IPI Resident Scholar Dr. Merrill Matthews, who has spent significant time researching and understanding prescription drug and health care innovation, describes how the Biden administration is abusing the “march in rights” permitted under the Bayh-Dole legislation in order to supposedly reduce prescription drug prices. He then explains how the Biden administration is also in danger of allowing the international TRIPs waiver provisions to further weaken patent protection. IPI Senior Research Fellow Bartlett Cleland relates these issues to the same kinds of tech transfer issues encountered in the tech industry, and IPI President Tom Giovanetti interjects thoughts of questionable value.
2023_04_21_Prescription_Drug_Innovation